程序性细胞死亡受体1配体及可溶性程序性细胞死亡受体1配体对肝细胞癌预后的预测价值与争议

冯国英; 史政荣

doi:10.3969/j.issn.1001-5256.2020.08.039

程序性细胞死亡受体1配体及可溶性程序性细胞死亡受体1配体对肝细胞癌预后的预测价值与争议

DOI: 10.3969/j.issn.1001-5256.2020.08.039

重庆医科大学附属第一医院肝胆外科

基金项目:

重庆市2019年科卫联合医学科研中青年高端人才项目(2019GDRC002)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 694
- HTML全文浏览量: 40
- PDF下载量: 180
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Value of programmed cell death ligand 1 and soluble programmed cell death ligand 1 in predicting the prognosis of hepatocellular carcinoma and related controversies

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University

Research funding:

摘要

摘要:
目前针对肝细胞癌（以下简称肝癌）的治疗手段多样,包括手术治疗、介入治疗、免疫治疗等,尽管如此,肝癌患者的5年生存率也仅为12.5%。影响肝癌预后的因素一直以来都是研究的焦点。近几年,随着程序性细胞死亡受体1 （PD-1）抑制剂在治疗肝癌方面的研究逐渐深入,作为其配体的PD-L1及可溶性PD-L1（s PD-L1）在肝癌免疫逃逸中的作用及预后预测价值也开始得到广泛关注与研究。重点阐述了现阶段PD-L1和s PD-L1作为免疫标志物在评价肝癌预后中的争议、共识及进展。
- 癌,肝细胞 /
- 程序性细胞死亡受体1 /
- 预后
Abstract:
At present,there are various treatment methods for hepatocellular carcinoma(HCC),including surgical treatment,interventional treatment,and immunotherapy,and even so,the five-year survival rate of HCC patients is only 12.5%.Influencing factors for the prognosis of HCC have always been the focus of research.With the in-depth research on programmed cell death protein 1(PD-1) inhibitors in the treatment of HCC in recent years,the role of programmed cell death ligand 1(PD-L1) and soluble programmed cell death ligand 1(s PD-L1),as the ligands of PD-1,in immune escape and their value in predicting prognosis have attracted more and more attention.This article elaborates on the current controversies,consensus,and advances in PD-L1 and s PD-L1 as immune markers in evaluating the prognosis of HCC.
- carcinoma,hepatocellular /
- programmed cell death protein 1 /
- prognosis

HTML全文

参考文献(44)

[1] HUANG S,YANG CL,ZHANG ZM. Research advances in targeted therapy for hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(11):2573-2577.(in Chinese)黄燊，杨成雷，张志明．肝细胞癌的靶向治疗[J]．临床肝胆病杂志，2019,35(11):2573-2577.

[2] MOCAN T,SPARCHEZ Z,CRACIUN R,et al. Programmed cell death protein-1(PD-1)/programmed death-ligand-1(PD-L1)axis in hepatocellular carcinoma:Prognostic and therapeutic perspectives[J]. Clin Transl Oncol,2019,21(6):702-712.

[3] ZHANG C,CHEN LH. Advances in immunoregulation of PD-1/PD-L1 in hepatocellular carcinoma[J]. Modern Hosp,2017,17(6):849-851.(in Chinese)张弛，陈龙华．PD-1/PD-L1在肝细胞癌中免疫调节作用的研究进展[J]．现代医院，2017,17(6):849-851.

[4] CHEN Y,WANG Q,SHI B,et al. Development of a sandwich ELISA for evaluating soluble PD-L1(CD274)in human sera of different ages as well as supernatants of PD-L1+cell lines[J]. Cytokine,2011,56(2):231-238.

[5] ROSSILLE D,GRESSIER M,DAMOTTE D,et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma:Results from a French multicenter clinical trial[J]. Leukemia,2014,28(12):2367-2375.

[6] WANG L,WANG H,CHEN H,et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma[J]. Oncotarget,2015,6(38):41228-41236.

[7] PAN SY,WANG ZX,ZHOU Y,et al. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J].J Clin Hepatol,2019,35(3):672-676.(in Chinese)潘思宇，王志鑫，周灜，等．PD-1/PD-L1信号通路在肝脏疾病中的功能及作用机制[J]．临床肝胆病杂志，2019,35(3):672-676.

[8] IWAI Y,HAMANISHI J,CHAMOTO K,et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci,2017,24(1):26.

[9] GAO Q,WANG XY,QIU SJ,et al. Overexpression of PD-L1significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res,2009,15(3):971-979.

[10] GU X,GAO XS,XIONG W,et al. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients[J]. Onco Targets Ther,2016,9:4805-4813.

[11] WU K,KRYCZEK I,CHEN L,et al. Kupffer cell suppression of CD8+T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J]. Cancer Res,2009,69(20):8067-8075.

[12] ZENG Z,SHI F,ZHOU L,et al. Upregulation of circulating PDL1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma[J]. PLo S One,2011,6(9):e23621.

[13] KAN G,DONG W. The expression of PD-L1 APE1 and P53in hepatocellular carcinoma and its relationship to clinical pathology[J]. Eur Rev Med Pharmacol Sci,2015,19(16):3063-3071.

[14] UMEMOTO Y,OKANO S,MATSUMOTO Y,et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J]. J Gastroenterol,2015,50(1):65-75.

[15] FINKELMEIER F,CANLI，TAL A,et al. High levels of the soluble programmed death-ligand(s PD-L1)identify hepatocellular carcinoma patients with a poor prognosis[J]. Eur J Cancer,2016,59:152-159.

[16] GABRIELSON A,WU Y,WANG H,et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC[J]. Cancer Immunol Res,2016,4(5):419-430.

[17] JUNG HI,JEONG D,JI S,et al. Overexpression of PD-L1and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Cancer Res Treat,2017,49(1):246-254.

[18] CALDERARO J,ROUSSEAU B,AMADDEO G,et al. Programmed death ligand 1 expression in hepatocellular carcinoma:Relationship with clinical and pathological features[J].Hepatology,2016,64(6):2038-2046.

[19] SEMAAN A,DIETRICH D,BERGHEIM D,et al. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia[J]. Virchows Arch,2017,470(2):185-196.

[20] HU K,WANG ZM,LI JN,et al. CLEC1B expression and PDL1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage[J]. Transl Oncol,2018,11(2):552-558.

[21] ZHONG JH,LUO CP,ZHANG CY,et al. Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients[J]. J Hepatocell Carcinoma,2017,4:11-13.

[22] WANG Q,LIU F,LIU L. Prognostic significance of PD-L1 in solid tumor:An updated meta-analysis[J]. Medicine(Baltimore),2017,96(18):e6369.

[23] PYO JS,KANG G,KIM JY. Prognostic role of PD-L1 in malignant solid tumors:A meta-analysis[J]. Int J Biol Markers,2017,32(1):e68-e74.

[24] LI JH,MA WJ,WANG GG,et al. Clinicopathologic significance and prognostic value of programmed cell death ligand 1(PD-L1)in Patients with hepatocellular carcinoma:A Metaanalysis[J]. Front Immunol,2018,9:2077.

[25] CHEN CL,PAN QZ,ZHAO JJ,et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma[J]. Oncoimmunology,2016,5(7):e1176653.

[26] SIDERAS K,BIERMANN K,VERHEIJ J,et al. PD-L1,Galectin-9 and CD8+tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma[J]. Oncoimmunology,2017,6(2):e1273309.

[27] LIU GM,LI XG,ZHANG YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection:A metaanalysis[J]. Cancer Cell Int,2019,19:22.

[28] COELHO MA,de CARNTRCESSON S,RANA S,et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA[J]. Immunity,2017,47(6):1083-1099. e6.

[29] TUMEH PC,HARVIEW CL,YEARLEY JH,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature,2014,515(7528):568-571.

[30] RIBAS A,WOLCHOK JD. Cancer immunotherapy using checkpoint blockade[J]. Science,2018,359(6382):1350-1355.

[31] SCHUMACHER TN,SCHREIBER RD. Neoantigens in cancer immunotherapy[J]. Science,2015,348(6230):69-74.

[32] XIANG X,YU PC,LONG D,et al. Prognostic value of PDL1 expression in patients with primary solid tumors[J]. Oncotarget,2018,9(4):5058-5072.

[33] HUANG CY,WANG Y,LUO GY,et al. Relationship between PD-L1 expression and CD8+T-cell immune responses in hepatocellular carcinoma[J]. J Immunother,2017,40(9):323-333.

[34] SIMON I,ZHUO S,CORRAL L,et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer[J]. Cancer Res,2006,66(3):1570-1575.

[35] TAKAHASHI N,IWASA S,SASAKI Y,et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer[J].J Cancer Res Clin Oncol,2016,142(8):1727-1738.

[36] EL-GHAMMAZ A,GADALLAH HA,KAMAL G,et al. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients[J]. Clin Exp Med,2018,18(4):505-512.

[37] AKUTSU Y,MURAKAMI K,KANO M,et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma[J]. Esophagus,2018,15(2):103-108.

[38] EL-GEBALY F,ABOU-SAIF S,ELKADEEM M,et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in egyptian patients[J].Curr Cancer Drug Targets,2019,19(11):896-905.

[39] KIM HJ,PARK S,KIM KJ,et al. Clinical significance of soluble programmed cell death ligand-1(sPD-L1)in hepatocellular carcinoma patients treated with radiotherapy[J]. Radiother Oncol,2018,129(1):130-135.

[40] HAN X,GU YK,LI SL,et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2019,145(2):303-312.

[41] BOMMARITO D,HALL C,TAAMS LS,et al. Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1[J]. Clin Exp Immunol,2017,188(3):455-466.

[42] CHANG B,HUANG T,WEI H,et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1(s PD-1)and soluble programmed death-ligand 1(s PD-L1)in patients with hepatocellular carcinoma[J].Cancer Immunol Immunother,2019,68(3):353-363.

[43] ELMEZAYEN HA,OKABE H,BABA Y,et al. Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma:Where does it come from?[J]. Surg Today,2020,50(6):569-576.

[44] NISHIDA N,KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int,2019,13(3):248-252.

施引文献

资源附件(0)

访问统计